What is Cerecin?
Cerecin operates as a sophisticated healthcare enterprise with nearly two decades of specialized focus on brain health innovation. The company distinguishes itself through a multi-modal approach, developing evidence-based solutions that span pharmaceuticals, medical foods, diagnostics, and e-health platforms. By addressing a broad spectrum of conditions—from mild memory impairment to severe neurological pathologies—Cerecin maintains a critical position in the life sciences market. Their operational model integrates rigorous scientific research with commercial scalability, positioning them as a leader in the development of next-generation neurological therapeutics and patient-centric medical devices.
How much funding has Cerecin raised?
Cerecin has raised a total of $233.9M across 10 funding rounds:
Series B
$7.5M
Series C
$35M
Private Equity
$26.1M
Series A
$12M
Private Equity
$9.5M
Series D
$11M
Debt
$3.9M
Debt
$4.9M
Private Equity
$84.1M
Other Financing Round
$40M
Series B (2006): $7.5M, investors not publicly disclosed
Series C (2008): $35M, investors not publicly disclosed
Private Equity (2008): $26.1M, investors not publicly disclosed
Series A (2009): $12M, investors not publicly disclosed
Private Equity (2010): $9.5M, investors not publicly disclosed
Series D (2010): $11M, investors not publicly disclosed
Debt (2011): $3.9M, investors not publicly disclosed
Debt (2012): $4.9M, investors not publicly disclosed
Private Equity (2012): $84.1M featuring Inventages Venture Capital Investment Inc.
Other Financing Round (2021): $40M backed by S&K Security Group and Hana Financial Investment Co.
Key Investors in Cerecin
Inventages Venture Capital Investment Inc.
A premier life-sciences and nutrition-focused venture capital firm that provides strategic guidance, executive recruitment, and access to global exit opportunities.
S&K Security Group
A specialized technology firm focused on high-availability surveillance and communication platforms, bringing a unique operational perspective to the investment landscape.
Hana Financial Investment Co.
A comprehensive financial services provider offering institutional-grade asset management and brokerage solutions to support long-term corporate growth.
What's next for Cerecin?
Following the latest capital injection, Cerecin is well-positioned to accelerate its R&D pipeline and expand its market footprint. The strategic focus will likely shift toward the commercialization of its advanced diagnostic tools and the scaling of its e-health product suite. By leveraging the expertise of its diverse investor base, the company is poised to navigate the complexities of global regulatory environments while maintaining its trajectory of innovation. Future growth will be defined by the successful transition of its clinical-stage assets into market-ready solutions, further solidifying its influence in the global neurology landscape.
See full Cerecin company page
